STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #473 by analyst upside · 2026-08-12
ABOS
Acumen Pharmaceuticals, Inc.
Healthcare · Market Cap $178M · P/E 0x
ANALYST PRICE TARGET
+199.6%
implied upside to consensus target
Current Price $2.47
Consensus Target $7.4
Bull Target $10.0
Bear Target $4.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
5
Hold
0
Sell
0
52-Week Low $1.19
52-Week High $3.6
YTD Return +22.3%
FUNDAMENTALS
Market Cap $178M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.85
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.19
52-Week High $3.6
Current Price $2.47
Bear Target $4.0
Bull Target $10.0
● Now $2.47 ● Target $7.4
TRADING DATA
Avg Volume 451K
YTD Return +22.3%
Analyst Count 5
Consensus Buy
Upside to Target +199.6%
Last Updated 2026-08-12

ANALYST SUMMARY

Acumen Pharmaceuticals, Inc. (ABOS) is currently trading at $2.47 with a Wall Street consensus price target of $7.4, implying potential upside of 199.6% over the next 12 months. 5 analysts currently cover ABOS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $10.0, while the most cautious has a target of $4.0.

ABOS operates in the Healthcare sector with a market capitalisation of $178M. The stock is up 22.3% year-to-date and is currently trading near the upper end of its 52-week range of $1.19 – $3.6.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ABOS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG reit
Buy → Buy 2026-03-26 38% win rate (8 calls)
BTIG - Reiterated
Buy → Buy 2026-03-16 38% win rate (8 calls)
BTIG - Reiterated
Buy → Buy 2026-01-27 38% win rate (8 calls)
B of A Securities - Reiterated
Buy → Buy 2025-11-18 Building track record
B of A Securities - Reiterated
Buy → Buy 2025-08-25 Building track record
Citigroup ● Initiated
Buy 2025-06-17 Building track record
UBS - Reiterated
Buy → Buy 2025-03-28 33% win rate (6 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-03-28 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →